Related Articles
00 / 00
Request an Appointment
Associate Professor, Department of Surgical Oncology
Gynecologic Oncology Fellowship Program Director
Endometrial (Uterine) Cancer, Vulvar Cancer, Cervical Cancer, Uterine Sarcoma, Ovarian & Primary Peritoneal Cancer
Minimally invasive surgery (laparoscopy and robotic surgery); endometrial cancer and hyperplasia; cervical cancer and dysplasia; vulvar cancer and dysplasia; vaginal cancer and dysplasia; gestational trophoblastic disease; surgical management of pelvic masses
I am excited to be a part of the gynecologic cancer patient care team at Fox Chase Cancer Center. I chose to work at Fox Chase to provide comprehensive, cutting-edge oncologic care by translating advances in research directly into my clinical practice.
As a gynecologic oncologist, I specialize in the surgical and medical management of tumors of the uterus, cervix, ovary, fallopian tube, vulva and vagina. I have extensive experience with complex open, laparoscopic and robotic surgery, which allows me to tailor a surgical plan based upon a patient’s needs and preferences. I also have expertise in administering intravenous and intraperitoneal chemotherapy for gynecologic malignancies. As a member of the multidisciplinary gynecologic cancer patient care team, I work closely with my colleagues in medical and radiation oncology to develop a comprehensive treatment plan that offers the best chance of cure for each patient.
I appreciate the challenges and commitment necessary to care for cancer patients. I understand that a cancer diagnosis can be overwhelming for patients and their families, and I always treat patients how I would want my family members to be treated: with honesty and compassion. I devote the time necessary to educate my patients on their options so they are best able to make an informed decision about their treatment.
Professionally, my research interests focus on endometriosis-associated ovarian cancer and hereditary ovarian cancer, including those resulting from BRCA1 or 2 mutations. The abundant resources available at Fox Chase, as well as my research experiences during my postdoctoral fellowship at the Magee-Womens Research Institute and as a clinical fellow at the University of Pennsylvania allow for me to participate in translational research and investigate innovative therapies to improve the quality of life for women with gynecologic malignancies.
Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, Adams SF. CTLA-4 Blockade Synergizes with PARP inhibition in BRCA1-deficient Ovarian cancer. Cancer Immunol Res. 2015 Jul 2. [Epub ahead of print]
Suryawanshi S, Budiu R, Elishaev E, Zhang L, Kim S, Tseng G, Mantia-Smaldone G, Ma T, Donnellan N, Lee T, Mansuria S, Edwards RP, Huang X and Vlad AM. Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res. 2014 Dec 1;20(23):6163-74. doi: 10.1158/1078-0432.CCR-14-1338. Epub 2014 Oct 7.
Mantia-Smaldone G, Ronner L, Blair A, Gamerman V, Morse C, Orsulic S, Rubin S, Gimotty P and Adams SF. The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1-deficienct ovarian tumors and can be exploited to improve treatment response in a mouse model. Gynecol Oncol. 2014 Jun;133(3):584-90. doi: 10.1016/j.ygyno.2014.03.565. Epub 2014 Mar 27.
Mantia-Smaldone G, Bagley LJ, Kasner SE and Chu CS. Vertebral artery dissection and cerebral infarction in a patient with recurrent ovarian cancer receiving bevacizumab. Gynecologic Oncology Case Reports. Volume 5, August 2013, 37-39. http://dx.doi.org/10.1016/j.gynor.2013.04.002.
Chiang CL, Kandalaft L, Tanyi J, Hagemann A, Motz G, Svoronos N, Smith L, Montone K, Mantia-Smaldone G, Nisenbaum H, Torigian D, Levine B, Mick R, Kalos M, Czerniecki B, Powell D, and Coukos G. A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside. Clin Cancer Res. 2013 Jul 15 [Epub ahead of print]
Mantia-Smaldone GM and Chu CS. A Review of Dendritic Cell Therapy for Cancer: Progress and Challenges. BioDrugs. 2013 Oct;27(5):453-68. doi: 10.1007/s40259-013-0030-9. Collapse
The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.
Patient comments